Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis.

Competing Interests: Declaration of competing interest R. Hindré reports travel support from Oxyvie and Boehringer Ingelheim, outside the submitted work. V. Besnard reports no conflict of interest. F. Kort reports travel support from Oxyvie, ADEP assistance and Boehringer Ingelheim, outside the submitted work. H. Nunes reports grants from Boehringer Ingelheim, Kinevant and Atyr pharma, outside the submitted work. D. Valeyre reports lecture honoraria from Boehringer Ingelheim and AstraZeneca, outside the submitted work. F. Jeny reports lecture honoraria from Boehringer Ingelheim, travel support from Oxyvie and payment from Wickenstones for an online expert questionnaire, outside the submitted work.